Facebook      Twitter

blank

blank

ONLINE LEARNING CENTER
print
 
Role of Newly-Approved HIV Antiretroviral Agents in Treatment-Experienced Patients (09HC08)


Amrita Kaur, DO and Sindy M. Paul, MD, MPH, FACPM

 

   
 
CREDIT IS NO LONGER AVAILABLE FOR THIS ACTIVITY.
Content is provided for informational purposes only.
 


Release Date: January 1, 2008
Expiration Date: EXPIRED (December 31, 2009)
Activity Code: 09HC08-DE01

The print version of this article included an error in the table: "Maraviroc Dosage Adjustments with Co-Administered CYP3A Inhibitors or Inducers" The table has been corrected re: Maraviroc dosage with CYP3A inducers. We apologize for the error and any difficulties or confusion that may have resulted.

To receive CE credit you should:

  • Review the activity in its entirety
  • Complete the post-test
  • Complete the activity evaluation

Upon successful completion of these requirements, you will receive a printable online credit statement.

If you have any questions about this process, please email the Center for Continuing and Outreach Education at ccoereg@ca.rutgers.edu or call CCOE Enrollment Services at (800) 227-4852.

As seen in the January 2008 edition of


 

© Copyright 2014, Rutgers, The State University of New Jersey, an equal opportunity, affirmative action institution.

Privacy Policy